清科創業(1945.HK)首日上市高開43.82%
格隆匯12月30日丨清科創業(1945.HK)今日首日上市高開43.82%報15.82港元,盤前成交2.35億港元,最新總市值47億港元。該股IPO價格為11港元,為招股區間上限。公司的股東和基石投資者陣容強大,包括紅杉、普華資本、海爾集團等。2017年至2019年,公司的總收入分別為1.29億元、1.64億元和1.67億元,年複合增長率達13.8%;同期錄得淨利潤為2206萬元、2716萬元及3879萬元,年複合增長率為36.9%。按2019年的收入計,公司是中國最大的股權投資綜合服務平台,公司作為行業龍頭優勢明顯。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.